Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next

Revolution Medicines (RVMD) is experiencing a 9.4% stock increase despite mounting losses, driven by the advancement of its drug daraxonrasib through FDA review for metastatic pancreatic cancer. The drug has seen significant demand, with over 2,000 patients receiving it through compassionate use even before potential approval. The company faces ongoing high cash burn and losses but has a strong cash balance and positive Phase 3 data for daraxonrasib, which analysts project could lead to substantial revenue and earnings by 2029.